Supplementary Material

**Assessing the suitability of CHA2DS2-VASc for predicting adverse limb events and cardiovascular outcomes in Peripheral Artery Disease patients**

**Yu-Tsung Cheng1, Fu-Lan Chang2, Po-Hsien Li3, Wen-Chien Lu4, Chien-Shan Chiu 5,6,7\***

1Cardiovascular Center, Taichung Veterans General Hospital, 1650 Section 4 Taiwan Boulevard, Xitun District, Taichung 40705, Taiwan

2Department of Nursing, Taichung Veterans General Hospital, 1650 Section 4 Taiwan Boulevard, Xitun District, Taichung 40705, Taiwan

3Department of Food and Nutrition, Providence University, 200, Section 7, Taiwan Boulevard, Shalu District, Taichung City 43301, Taiwan

4Department of Food and Beverage Management, Chung-Jen Junior College of Nursing, Health Sciences and Management, 217, Hung-Mao-Pi, Chia-Yi City 60077, Taiwan

5Department of Dermatology, Taichung Veterans General Hospital, 1650 Section 4 Taiwan Boulevard, Xitun District, Taichung 40705, Taiwan

6Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, 145 Xingda Road, South District, Taichung 402, Taiwan

7College of Biotechnology and Bioresources, Da-Yeh University, 168, University Road, Dacun, Changhua 51591, Taiwan

**\* Correspondence:**Chien-Shan Chiu

Department of Dermatology, Taichung Veterans General Hospital, 1650 Section 4 Taiwan Boulevard, Xitun District, Taichung 40705, Taiwan

Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, 145 Xingda Road, South District, Taichung 402, Taiwan

College of Biotechnology and Bioresources, Da-Yeh University, 168, University Road, Dacun, Changhua 51591, Taiwan

Email: chienshan@vghtc.gov.tw

Running Title: Can CHA2DS2-VASc predict Limb and CVD events?

# Supplementary Figures and Tables




Figure S1. The distribution of PAD samples based on (a) CHA2DS2-VASc and (b) MCR scores

**Table S1. Description of Rutherford classifications**

|  |  |  |  |
| --- | --- | --- | --- |
| Grade | Category | Clinical description | Objective criteria |
| 0 | 0 | Asymptomatic – no hemodynamically significant occlusive disease | Normal treadmill test and ABI ≥ 0.9 |
|  | 1 | Mild claudication | Treadmill test completed. AP after exercise <50 mmHg |
| I | 2 | Moderate claudication | Between categories 1 and 3 |
|  | 3 | Severe claudication | Cannot complete treadmill test and Ankle pressure (AP) after exercise <50 mmHg |
| II | 4 | Ischemic rest pain | Resting Ankle pressure (AP) <40 mmHg, flat or barely pulsatile ankle or metatarsal PVR, TP <30 mmHg |
| III | 5 | Minor tissue loss – non-healing ulcer, focal gangrene with diffuse pedal ischemia | Resting AP <60 mmHg, ankle or metatarsal PVR flat or barely pulsatile, TP <40 mmHg |
|  | 6 | Major tissue loss- extending above TM level, functional foot no longer salvageable | Similar to category 5 |

AP: Ankle pressure, PVR: pulse volume recording, TP: toe pressure

**Table S2.** Demographic and clinico-pathological characteristics for major adverse limb events (MALE) and major adverse cardiovascular events (MACE)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | MALE  (n=193) | no MALE  (n= 310) | P-value | MACE  (n=49) | No MACE  (n = 454) | P-value |
| MCR score |  |  |  |  |  |  |
| =3 | 31 (16.06) | 69 (22.26) |  | 3 (6.12) | 97 (21.37) |  |
| =4 | 49 (25.39) | 66 (21.29) |  | 13 (26.53) | 102 (22.47) |  |
| =5 | 63 (32.64) | 77 (24.83) |  | 16 (32.65) | 124 (27.31) |  |
| =6 | 50 (25.91) | 98 (31.61) | 0.05\* | 17 (34.69) | 131 (28.85) | 0.0002\* |
|  |  |  |  |  |  |  |
| Age | 69.83 ± 12.44 | 71.35 ± 12.34 | 0.182 | 71.75 ± 10.85 | 70.67 ± 12.55 | 0.512 |
| Sex (Male) | 123 (63.73) | 203 (65.48) | 0.701 | 34 (69.39) | 292 (64.31) | 0.537 |
| BMI | 23.687 ± 3.665 | 24.14 ± 4.04 | 0.191 | 24.15 ± 3.502 | 23.94 ± 3.95 | 0.713 |
| CHF (C) | 89 (46.11) | 149 (48.60) | 0.7136 | 34 (69.39) | 204 (44.93) | 0.001\* |
| HTN | 165 (85.49) | 271 (87.42) | 0.589 | 47 (95.92) | 389 (85.68) | 0.045\* |
| DM | 158 (81.86) | 218 (70.32) | 0.004\* | 44 (89.80) | 332 (73.12) | 0.009\* |
| Stroke (S)/TIA | 31 (16.06) | 60 (19.35) | 0.405 | 11 (22.24) | 80 (17.62) | 0.434 |
| Vascular Disease | 193 (100) | 310 (100) | 1 | 49 (100) | 454 (100) | 1 |
| HPL | 99 (51.29) | 142 (45.80) | 0.235 | 30 (61.22) | 211 (46.48) | 0.05\* |
| SMK | 71 (36.78) | 124 (40) | 0.51 | 23 (46.93) | 172 (37.88) | 0.221 |
| CAD | 101 (52.33) | 162 (52.25) | 1 | 33 (67.49) | 230 (50.66) | 0.034\* |
| CABG | 18 (9.33) | 35 (11.29) | 0.551 | 10 (20.41) | 43 (9.47) | 0.026\* |
| PCI | 95 (49.22) | 144 (46.5) | 0.582 | 30 (61.22) | 209 (46.03) | 0.05 |
| Old MI | 24 (12.43) | 55 (17.74) | 0.13 | 17 (34.69) | 62 (13.66) | 0.0005\* |
| COPD | 7 (3.63) | 14 (4.52) | 0.819 | 5 (10.20) | 16 (3.52) | 0.043\* |
| CKD | 120 (62.17) | 199 (64.19) | 0.703 | 41 (83.67) | 278 (61.23) | 0.001\* |
| HD/PD | 73 (37.82) | 108 (34.83) | 0.505 | 22 (44.90) | 159 (35.02) | 0.209 |
| Cr | 3.484 ± 3.345 | 3.128 ± 2.846 | 0.236 | 4.237 ± 2.964 | 3.15 ± 3.03 | 0.024\* |
| Af | 41 (21.24) | 79 (25.48) | 0.2847 | 19 (38.77) | 101 (22.24) | 0.013\* |
| Imd | 6 (3.11) | 15 (4.83) | 0.492 | 0 (0) | 21 (4.62) | 0.248 |
|  |  |  |  |  |  |  |
| HbA1C | 7.682 ± 2.017 | 7.104 ± 1.727 | 0.001\* | 7.716 ± 1.796 | 7.27 ± 1.876 | 0.114 |
| Cholesterol | 149.63 ± 41.227 | 149.66 ± 38.31 | 0.992 | 143.38 ± 27.496 | 150.33 ± 40.46 | 0.115 |
| LDL | 82.87 ± 34.177 | 83.673 ± 32.87 | 0.796 | 76.22 ± 30.17 | 84.14 ± 33.61 | 0.089 |
| HDL | 42.238 ± 14.915 | 43.37 ± 15.40 | 0.412 | 43.979 ± 14.09 | 42.83 ± 15.34 | 0.591 |
| TG | 131.59 ± 84.48 | 130.41 ± 83.48 | 0.878 | 123.53 ± 71.24 | 131.66 ± 85.06 | 0.46 |
| Glu | 154.88 ± 74.85 | 139.82 ± 65.398 | 0.021\* | 149.53 ± 59.80 | 145.18 ± 70.50 | 0.636 |
|  |  |  |  |  |  |  |
| ASA | 149 (77.20) | 236 (76.13) | 0.829 | 39 (79.59) | 346 (76.21) | 0.723 |
| clopidgrel | 165 (85.49) | 262 (84.52) | 0.799 | 44 (89.79) | 383 (84.36) | 0.403 |
| cilostazol | 121 (62.69) | 180 (58.06) | 0.349 | 29 (59.18) | 272 ( 59.91) | 1 |
| pentoxyphilline | 1 (0.51) | 0 (0) | 0.383 | 0 (0) | 1 (0.22) | 1 |
| direct oral anticoagulant (DOAC) | 25 (12.95) | 48 (15.48) | 0.515 | 7 (14.29) | 66 (14.54) | 1 |
| ACEIARB | 84 (43.52) | 136 (43.87) | 1 | 17 (34.69) | 203 (43.39) | 0.225 |
| statin | 106 (54.92) | 177 (57.09) | 0.645 | 23 (46.93) | 260 (55.51) | 0.175 |
| Betablocker | 76 (39.37) | 113 (36.45) | 0.509 | 15 (30.61) | 174 (37.23) | 0.352 |
| CCB | 74 (38.34) | 127 (40.97) | 0.575 | 15 (30.61) | 180 (37.89) | 0.280 |
| Insulin | 45 (23.32) | 61 (19.68) | 0.368 | 13 (26.53) | 93 (19.38) | 0.356 |
| **Rutherford classification** |  |  |  |  |  |  |
| 1 | 0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| 2 | 0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| 3 | 0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| 4 | 35 (18.13) | 95 (30.64) | 0.001\* | 5 (10.20) | 125 (27.53) | 0.009\* |
| 5 | 133 (68.91) | 183 (59.03) | 0.029\* | 35 (71.43) | 281 (61.89) | 0.215 |
| 6 | 25 (12.95) | 32 (10.32) | 0.575 | 9 (18.37) | 48 (10.57) | 0.15 |
| **Target vessel** |  |  |  |  |  |  |
| CIA | 12 (6.22) | 29 (9.35) | 0.243 | 4 (8.16) | 37 (8.15) | 1 |
| EIA | 10 (5.18) | 35 (11.29) | 0.024\* | 5 (10.20) | 40 (8.81) | 0.791 |
| CFA | 10 (5.18) | 17 (5.48) | 1 | 3 (6.12) | 24 (5.29) | 0.739 |
| SFA | 113 (58.54) | 172 (55.48) | 0.518 | 27 (55.10) | 258 (56.83) | 0.879 |
| ATA | 100 (51.81) | 148 (47.74) | 0.409 | 26 (53.06) | 222 (48.90) | 0.653 |
| Popliteal | 50 (25.91) | 57 (18.39) | 0.056\* | 10 (20.41) | 97 (21.37) | 1 |
| Peroneal artery | 46 (23.83) | 50 (16.13) | 0.036\* | 13 (26.53) | 83 (18.28) | 0.181 |
| Tibiofibular TP trunk | 25 (12.95) | 39 (12.58) | 0.891 | 3 (6.12) | 61 (13.44) | 0.178 |
| PTA | 88 (45.59) | 108 (34.84) | 0.018\* | 15 (30.61) | 181 (39.87) | 0.221 |
| DPA | 10 (5.18) | 5 (1.61) | 0.029\* | 1 (2.04) | 14 (3.08) | 1 |
| Plantar artery | 15 (7.78) | 8 (2.58) | 0.008\* | 2 (4.08) | 21 (4.63) | 1 |

BMI: body mass index; CHF (C): HTN: hypertension; DM: diabetes mellitus; Stroke (S)/TIA; HPL: hyperlipidemia; SMK: smoking status; CAD: coronary artery disease; CABG: Coronary Artery Bypass Graft; PCI: Percutaneous coronary intervention; MI: myocardial infarction; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; HD/PD: hemodialysis/peritoneal dialysis; Cr: creatinine; Af: atrial fibrillation; Imd: immune-related disease; HbA1C: hemoglobin A1C, LDL: low-density lipoprotein; HDL: high-density lipoprotein; TG: triglyceride; Glu: glucose; ASA: Acetylsalicylic acid; ACEIARB: Angiotensin-Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB); CCB: Calcium channel blockers; CIA: common iliac artery; EIA: external iliac artery; CFA: common femoral artery; SFA: superficial femoral artery; ATA: anterior tibial artery; Tibiofibular TP (tibioperoneal) trunk; PTA: posterior tibial artery; DPA: dorsalis pedis artery.

Table S3. Demographic and clinico-pathological characteristics for outcome major adverse limb events (MALE) + major adverse cardiovascular events (MACE).

|  |  |  |  |
| --- | --- | --- | --- |
|  | MALE +MACE  (n=224) | no MALE+MACE  (n= 279) | P-value |
| MCR score |  |  |  |
| =3 | 34 (15.17) | 66 (23.66) |  |
| =4 | 57 (25.45) | 58 (20.79) |  |
| =5 | 70 (31.25) | 70 (25.09) |  |
| =6 | 63 (28.13) | 85 (30.47) | 0.05\* |
|  |  |  |  |
| Age | 69.99 ± 12.26 | 71.39 ± 1247 | 0.208 |
| Sex (Male) | 147 (65.62) | 179 (64.16) | 0.778 |
| BMI | 23.82 ± 3.703 | 24.09 ± 4.06 | 0.443 |
| CHF (C) | 115 (51.34) | 123 (44.09) | 0.107 |
| HTN | 196 (87.50) | 240 (86.02) | 0.692 |
| DM | 185 (82.59) | 191 (68.46) | 0.0002\* |
| Stroke (S)/TIA | 37 (16.52) | 54 (19.35) | 0.485 |
| Vascular Disease | 224 (100) | 279 (100) | 1 |
| HPL | 117 (52.23) | 124 (44.44) | <0.0001\* |
| SMK | 90 (40.18) | 105 (37.63) | 0.51 |
| CAD | 125 (55.80) | 138 (49.46) | 1 |
| CABG | 25 (11.16) | 28 (10.03) | 0.770 |
| PCI | 117 (52.23) | 122 (43.72) | 0.05\* |
| Old MI | 37 (16.52) | 42 (15.05) | 0.712 |
| COPD | 11 (4.91) | 10 (3.58) | 0.506 |
| CKD | 144 (64.29) | 175 (62.72) | 0.78 |
| HD/PD | 86 (38.39) | 95 (34.05) | 0.350 |
| Cr | 3.601 ± 3.282 | 3.002 ± 2.826 | 0.036\* |
| Af | 52 (23.21) | 68 (24.37) | 0.833 |
| Imd | 6 (2.68) | 15 (5.38) | 0.178 |
|  |  |  |  |
| HbA1C | 7.610 ± 1.939 | 7.097 ± 1.769 | 0.002\* |
| Cholesterol | 148.69 ± 39.61 | 150.44 ± 39.31 | 0.622 |
| LDL | 82.00 ± 34.18 | 84.46 ± 32.68 | 0.414 |
| HDL | 42.58 ± 14.918 | 43.22 ± 15.46 | 0.639 |
| TG | 128.89 ± 82.27 | 132.45 ± 85.10 | 0.636 |
| Glu | 152.55 ± 72.53 | 140.03 ± 66.56 | 0.046\* |
|  |  |  |  |
| ASA | 171 (76.34) | 214 (76.70) | 1 |
| clopidgrel | 194 (86.61) | 233 (83.51) | 0.381 |
| cilostazol | 141 (62.95) | 160 (57.35) | 0.234 |
| pentoxyphilline | 1 (0.46) | 0 (0) | 0.445 |
| direct oral anticoagulant (DOAC) | 30 (13.39) | 43 (15.41) | 0.610 |
| ACEIARB | 94 (41.96) | 126 (45.16) | 0.526 |
| statin | 121 (54.02) | 162 (58.06) | 0.367 |
| Betablocker | 82 (36.61) | 107 (38.35) | 0.711 |
| CCB | 86 (38.39) | 115 (41.22) | 0.523 |
| Insulin | 56 (25) | 50 (17.92) | 0.061 |
| **Rutherford classification** |  |  |  |
| 1 | 0 (0) | 0 (0) | 1 |
| 2 | 0 (0) | 0 (0) | 1 |
| 3 | 0 (0) | 0 (0) | 1 |
| 4 | 38 (16.96) | 92 (32.97) | <0.0001\* |
| 5 | 156 (69.64) | 160 (57.35) | 0.005\* |
| 6 | 25 (13.39) | 27 (9.68) | 0.659 |
| **Target vessel** |  |  |  |
| CIA | 14 (6.25) | 27 (9.68) | 0,191 |
| EIA | 13 (5.28) | 32 (11.47) | 0.028\* |
| CFA | 11 (4.91) | 16 (5.73) | 0.842 |
| SFA | 131 (58.48) | 154 (55.20) | 0.470 |
| ATA | 117 (52.23) | 131 (46.95) | 0.251 |
| Popliteal | 55 (24.55) | 52 (18.64) | 0.125 |
| Peroneal artery | 51 (22.77) | 45 (16.13) | 0.067 |
| Tibiofibular TP trunk | 29 (12.95) | 35 (12.54) | 0.893 |
| PTA | 98 (43.75) | 98 (35.12) | 0.053 |
| DPA | 10 (4.46) | 5 (1.79) | 0.112 |
| Plantar artery | 15 (6.69) | 8 (2.87) | 0.053 |

BMI: body mass index; CHF (C): HTN: hypertension; DM: diabetes mellitus; Stroke (S)/TIA; HPL: hyperlipidemia; SMK: smoking status; CAD: coronary artery disease; CABG: Coronary Artery Bypass Graft; PCI: Percutaneous coronary intervention; MI: myocardial infarction; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; HD/PD: hemodialysis/peritoneal dialysis; Cr: creatinine; Af: atrial fibrillation; Imd: immune-related disease; HbA1C: hemoglobin A1C, LDL: low-density lipoprotein; HDL: high-density lipoprotein; TG: triglyceride; Glu: glucose; ASA: Acetylsalicylic acid; ACEIARB: Angiotensin-Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB); CCB: Calcium channel blockers; CIA: common iliac artery; EIA: external iliac artery; CFA: common femoral artery; SFA: superficial femoral artery; ATA: anterior tibial artery; Tibiofibular TP (tibioperoneal) trunk; PTA: posterior tibial artery; DPA: dorsalis pedis artery.

Table S4. Calibration analysis for years 1-5 based on multivariate-adjusted MCR models for MALE.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| year | diff\_1 | diff\_2 | diff\_3 | diff\_4 | diff\_5 | diff\_6 | diff\_7 | diff\_8 | diff\_9 | diff\_10 | Avg. | Std. dev |
| 1 | 0.034 | -0.270 | 0.050 | -0.067 | 0.0913 | 0.038 | 0.212 | 0.083 | 0.117 | 0.141 | 0.043 | 0.132 |
| 2 | 0.173 | 0.237 | 0.400 | 0.232 | 0.1515 | 0.352 | 0.432 | 0.422 | 0.413 | 0.391 | 0.320 | 0.110 |
| 3 | 0.074 | 0.425 | 0.487 | 0.475 | 0.3788 | 0.400 | 0.283 | 0.392 | 0.472 | 0.534 | 0.392 | 0.132 |
| 4 | 0.243 | 0.486 | 0.453 | 0.515 | 0.3101 | 0.431 | 0.429 | 0.498 | 0.539 | 0.479 | 0.438 | 0.093 |
| 5 | 0.445 | 0.420 | 0.548 | 0.508 | 0.5168 | 0.499 | 0.531 | 0.467 | 0.607 | 0.590 | 0.513 | 0.060 |

Table S5. Calibration analysis for year 1 - year 5 based on multivariate-adjusted traditional models for MALE

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| year | diff\_1 | diff\_2 | diff\_3 | diff\_4 | diff\_5 | diff\_6 | diff\_7 | diff\_8 | diff\_9 | diff\_10 | Avg. | Std. Dev |
| 1 | 0.021 | -0.282 | 0.062 | -0.076 | 0.0908 | 0.048 | 0.222 | 0.085 | 0.132 | 0.138 | 0.044 | 0.139 |
| 2 | 0.146 | 0.253 | 0.387 | 0.209 | 0.1498 | 0.369 | 0.448 | 0.425 | 0.428 | 0.388 | 0.320 | 0.119 |
| 3 | 0.064 | 0.438 | 0.492 | 0.449 | 0.3946 | 0.416 | 0.307 | 0.387 | 0.478 | 0.518 | 0.394 | 0.131 |
| 4 | 0.235 | 0.502 | 0.434 | 0.507 | 0.3606 | 0.458 | 0.457 | 0.490 | 0.551 | 0.447 | 0.444 | 0.089 |
| 5 | 0.399 | 0.441 | 0.531 | 0.488 | 0.6104 | 0.527 | 0.556 | 0.434 | 0.582 | 0.587 | 0.516 | 0.072 |

Table S6. Calibration analysis for years 1-5 based on multivariate-adjusted MCR models for MACE.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| year | diff\_1 | diff\_2 | diff\_3 | diff\_4 | diff\_5 | diff\_6 | diff\_7 | diff\_8 | diff\_9 | diff\_10 | Avg. | Std. dev. |
| 1 | -0.025 | 0.001 | 0.039 | 0.025 | 0.0002 | -0.016 | 0.064 | -0.092 | 0.072 | 0.072 | 0.014 | 0.052 |
| 2 | 0.114 | 0.020 | 0.024 | 0.094 | 0.0460 | 0.105 | 0.084 | -0.010 | 0.021 | 0.022 | 0.052 | 0.043 |
| 3 | 0.129 | -0.003 | 0.080 | 0.013 | 0.1947 | 0.127 | 0.130 | 0.049 | 0.095 | 0.093 | 0.091 | 0.059 |
| 4 | 0.207 | 0.122 | 0.026 | 0.097 | 0.0386 | 0.180 | 0.159 | 0.036 | 0.092 | 0.118 | 0.108 | 0.062 |
| 5 | 0.362 | -0.249 | 0.093 | 0.119 | 0.2520 | 0.190 | 0.182 | 0.125 | -0.098 | 0.189 | 0.117 | 0.174 |

Table S7. Calibration analysis for years 1-5 based on multivariate-adjusted traditional models for MACE.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| year | diff\_1 | diff\_2 | diff\_3 | diff\_4 | diff\_5 | diff\_6 | diff\_7 | diff\_8 | diff\_9 | diff\_10 | Avg. | Std. dev. |
| 1 | -0.025 | -0.001 | 0.037 | 0.023 | 0.0007 | -0.013 | 0.065 | -0.094 | 0.071 | 0.070 | 0.013 | 0.052 |
| 2 | 0.116 | 0.021 | 0.022 | 0.091 | 0.0461 | 0.104 | 0.086 | -0.014 | 0.023 | 0.020 | 0.051 | 0.044 |
| 3 | 0.137 | 0.003 | 0.079 | 0.015 | 0.1930 | 0.122 | 0.133 | 0.062 | 0.101 | 0.090 | 0.093 | 0.058 |
| 4 | 0.211 | 0.121 | 0.024 | 0.108 | 0.0181 | 0.171 | 0.158 | 0.045 | 0.097 | 0.114 | 0.107 | 0.064 |
| 5 | 0.378 | -0.249 | 0.075 | 0.111 | 0.2774 | 0.181 | 0.181 | 0.186 | -0.079 | 0.175 | 0.124 | 0.178 |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| year | diff\_1 | diff\_2 | diff\_3 | diff\_4 | diff\_5 | diff\_6 | diff\_7 | diff\_8 | diff\_9 | diff\_10 | Avg. | Std.dev. |
| 1 | 0.003 | -0.253 | 0.060 | -0.069 | 0.0614 | 0.043 | 0.269 | 0.004 | 0.135 | 0.172 | 0.043 | 0.141 |
| 2 | 0.272 | 0.319 | 0.381 | 0.276 | 0.1557 | 0.371 | 0.420 | 0.394 | 0.348 | 0.425 | 0.336 | 0.083 |
| 3 | 0.146 | 0.540 | 0.533 | 0.436 | 0.4538 | 0.524 | 0.416 | 0.351 | 0.453 | 0.477 | 0.433 | 0.116 |
| 4 | 0.340 | 0.605 | 0.390 | 0.536 | 0.3836 | 0.511 | 0.509 | 0.395 | 0.561 | 0.626 | 0.486 | 0.101 |
| 5 | 0.737 | -0.313 | 0.660 | 0.581 | 0.5705 | 0.551 | 0.526 | 0.514 | 0.430 | 0.708 | 0.496 | 0.299 |

Table S8. Calibration analysis for years 1-5 based on multivariate-adjusted MCR models for MALE + MACE

Table S9. Calibration analysis for years 1-5 based on multivariate-adjusted traditional model for MALE + MACE

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| year | diff\_1 | diff\_2 | diff\_3 | diff\_4 | diff\_5 | diff\_6 | diff\_7 | diff\_8 | diff\_9 | diff\_10 | Avg. | Std. dev. |
| 1 | -0.006 | -0.265 | 0.066 | -0.079 | 0.0603 | 0.054 | 0.274 | 0.006 | 0.149 | 0.170 | 0.043 | 0.147 |
| 2 | 0.253 | 0.324 | 0.367 | 0.257 | 0.1549 | 0.393 | 0.427 | 0.396 | 0.362 | 0.424 | 0.336 | 0.088 |
| 3 | 0.143 | 0.539 | 0.533 | 0.423 | 0.4707 | 0.537 | 0.433 | 0.345 | 0.463 | 0.462 | 0.435 | 0.119 |
| 4 | 0.341 | 0.605 | 0.373 | 0.536 | 0.4296 | 0.529 | 0.525 | 0.379 | 0.580 | 0.600 | 0.490 | 0.100 |
| 5 | 0.715 | -0.296 | 0.592 | 0.568 | 0.6617 | 0.572 | 0.542 | 0.543 | 0.417 | 0.698 | 0.501 | 0.293 |